特集 : 国別レポートが13,000件から検索可能になりました!

特集 : 海外市場の委託調査がセミカスタムベースでお手軽にできます

株式会社グローバルインフォメーション
表紙
市場調査レポート
商品コード
232792

慢性腎疾患(慢性腎不全):パイプライン製品の分析

Chronic Kidney Disease (Chronic Renal Failure) - Pipeline Review, H1 2020

出版日: | 発行: Global Markets Direct | ページ情報: 英文 276 Pages | 納期: 即納可能 即納可能とは

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=105.84円
慢性腎疾患(慢性腎不全):パイプライン製品の分析
出版日: 2020年04月30日
発行: Global Markets Direct
ページ情報: 英文 276 Pages
納期: 即納可能 即納可能とは
担当者のコメント
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 図表
  • 目次
概要

慢性腎疾患とは腎機能がゆっくりと時間をかけて失われていく疾患であり、兆候および症状には、悪心、嘔吐、食欲減退、疲労感、筋力低下、睡眠障害、しゃっくり、足・足首のむくみなどがあります。年齢、糖尿病、高血圧、心臓疾患、喫煙、肥満、高コレステロール値などが素因となっています。

当レポートでは、世界における慢性腎疾患(慢性腎不全)治療薬のパイプラインについて取り上げ、現在の開発パイプラインの状況や最新動向、薬剤プロファイル、主要企業および開発中の製品レビューなどをお届けいたします。

目次

イントロダクション

  • 分析範囲

慢性腎疾患(慢性腎不全)の概要

治療薬の開発

  • 慢性腎疾患(慢性腎不全)向けパイプライン製品:概要
  • 慢性腎疾患(慢性腎不全)向けパイプライン製品:比較分析

慢性腎疾患(慢性腎不全):開発中の治療薬:企業別

慢性腎疾患(慢性腎不全):開発中の治療薬:大学・研究機関別

慢性腎疾患(慢性腎不全):パイプライン製品の概況

  • 後期段階の製品
  • 治験段階の製品
  • 初期段階の製品
  • 開発段階が不明の製品

慢性腎疾患(慢性腎不全):開発中の製品:企業別

慢性腎疾患(慢性腎不全):開発中の製品:大学・研究機関別

慢性腎疾患(慢性腎不全):治療薬開発に従事している企業

  • Acceleron Pharma, Inc.
  • Angion Biomedica Corp.
  • Astellas Pharma Inc.
  • Bayer AG
  • Bio-inRen
  • BioAegis Therapeutics, Inc.
  • Boryung Pharmaceutical Co., Ltd.
  • Complexa, Inc.
  • Evotec AG
  • F. Hoffmann-La Roche Ltd.
  • Gilead Sciences, Inc.
  • Intercept Pharmaceuticals, Inc.
  • Ionis Pharmaceuticals, Inc.
  • Lupin Limited
  • 日本臓器製薬
  • OPKO Health, Inc.
  • Otsuka Holdings Co., Ltd.
  • Prismic Pharmaceuticals, Inc.
  • Prolong Pharmaceuticals, LLC
  • ProMetic Life Sciences Inc.
  • Reata Pharmaceuticals, Inc.
  • Red Glead Discovery AB
  • RegenMedTX, LLC
  • Resverlogix Corp.
  • Sphaera Pharma Pvt. Ltd.
  • Stelic Institute & Co., Inc.
  • Thrasos Therapeutics Inc.
  • 東レ
  • VBS Pharmaceuticals
  • Vicore Pharma AB

慢性腎疾患(慢性腎不全):治療薬の評価

  • 単剤治療薬
  • コンビネーション製品
  • 標的別
  • 作用機序別
  • 投与経路別
  • 分子タイプ別

薬剤プロファイル

  • (palmidrol + silibinin)
  • ambrisentan
  • ANG-3070
  • ANG-3281
  • ANG-3586
  • ANG-4011
  • apabetalone
  • AS-2444697
  • ASP-6858
  • bardoxolone methyl
  • BR-05001
  • BRN-1889
  • C-21
  • calcium succinate
  • CAR Peptide
  • cardiotoxin
  • Cell Therapy for Chronic Kidney Disease and Type-2 diabetes
  • CXA-10
  • Drug for Kidney Diseases
  • Drugs to Inhibit CYP24 for Secondary Hyperparathyroidism, Chronic Kidney Disease and Oncology
  • finerenone
  • INT-767
  • IONIS-FXIRx
  • KBP-5074
  • NZ-419
  • obinutuzumab
  • PBI-4050
  • PBI-4419
  • Protein to Activate BMP-7 for Kidney Diseases, Metabolic Disorders and Osteoarthritis
  • Recombinant Plasma Gelsolin Replacement for Renal Disease
  • rivaroxaban
  • Sanguinate
  • など

最新のパイプライン動向

休止中のプロジェクト

開発が中止された製品

製品開発マイルストーン

  • 注目のニュース・プレスリリース

付録

図表

図表

List of Tables

  • Number of Products under Development for Chronic Kidney Disease (Chronic Renal Failure), H1 2020
  • Number of Products under Development by Companies, H1 2020
  • Number of Products under Development by Companies, H1 2020 (Contd..1), H1 2020
  • Number of Products under Development by Companies, H1 2020 (Contd..2), H1 2020
  • Number of Products under Development by Universities/Institutes, H1 2020
  • Products under Development by Companies, H1 2020
  • Products under Development by Companies, H1 2020 (Contd..1), H1 2020
  • Products under Development by Companies, H1 2020 (Contd..2), H1 2020
  • Products under Development by Companies, H1 2020 (Contd..3), H1 2020
  • Products under Development by Universities/Institutes, H1 2020
  • Number of Products by Stage and Target, H1 2020
  • Number of Products by Stage and Target, H1 2020 (Contd..1), H1 2020
  • Number of Products by Stage and Mechanism of Action, H1 2020
  • Number of Products by Stage and Mechanism of Action, H1 2020 (Contd..1), H1 2020
  • Number of Products by Stage and Route of Administration, H1 2020
  • Number of Products by Stage and Molecule Type, H1 2020
  • Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Algernon Pharmaceuticals Inc, H1 2020
  • Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Algomedix Inc, H1 2020
  • Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Allena Pharmaceuticals Inc, H1 2020
  • Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Angion Biomedica Corp, H1 2020
  • Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by apceth Biopharma GmbH, H1 2020
  • Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Arch Biopartners Inc, H1 2020
  • Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Aronora Inc, H1 2020
  • Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by AstraZeneca Plc, H1 2020
  • Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Bayer AG, H1 2020
  • Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by BioAegis Therapeutics Inc, H1 2020
  • Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Boehringer Ingelheim International GmbH, H1 2020
  • Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Boryung Pharmaceutical Co Ltd, H1 2020
  • Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Cadila Healthcare Ltd, H1 2020
  • Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Cellmid Ltd, H1 2020
  • Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Cinkate Corp, H1 2020
  • Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Corvidia Therapeutics Inc, H1 2020
  • Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Daiichi Sankyo Co Ltd, H1 2020
  • Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by DiaMedica Therapeutics Inc, H1 2020
  • Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Dimerix Ltd, H1 2020
  • Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Dizal (Jiangsu) Pharmaceutical Co Ltd, H1 2020
  • Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by DJS Antibodies Ltd, H1 2020
  • Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by DURECT Corp, H1 2020
  • Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Evotec SE, H1 2020
  • Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by G3 Pharmaceuticals Inc, H1 2020
  • Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by GNI Group Ltd, H1 2020
  • Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Icagen Inc, H1 2020
  • Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Indalo Therapeutics Inc, H1 2020
  • Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by INVENT Pharmaceuticals Inc, H1 2020
  • Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by ITB-Med AB, H1 2020
  • Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Kaleido Biosciences Inc, H1 2020
  • Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by KBP BioSciences Co Ltd, H1 2020
  • Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by KidneyCure Ltd, H1 2020
  • Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Kintai Therapeutics Inc, H1 2020
  • Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Klotho Therapeutics Inc, H1 2020
  • Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Liminal BioSciences Inc, H1 2020
  • Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Merck & Co Inc, H1 2020
  • Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Meridigen Biotech Co Ltd, H1 2020
  • Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Novartis AG, H1 2020
  • Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by OPKO Health Inc, H1 2020
  • Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Opsidio LLC, H1 2020
  • Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by OrthoTrophix Inc, H1 2020
  • Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by ProKidney LLC, H1 2020
  • Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Reata Pharmaceuticals Inc, H1 2020
  • Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Redx Pharma Plc, H1 2020
  • Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Reliance Life Sciences Pvt Ltd, H1 2020
  • Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Renibus Therapeutics Inc, H1 2020
  • Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Resverlogix Corp, H1 2020
  • Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Sarfez Pharmaceuticals Inc, H1 2020
  • Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Scohia Pharma Inc, H1 2020
  • Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Sentien Biotechnologies Inc, H1 2020
  • Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Sphaera Pharma Pte Ltd, H1 2020
  • Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Unicocell Biomed Co Ltd, H1 2020
  • Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Unity Biotechnology Inc, H1 2020
  • Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Vascular BioSciences, H1 2020
  • Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by VESSL Therapeutics Ltd, H1 2020
  • Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Vidasym Inc, H1 2020
  • Chronic Kidney Disease (Chronic Renal Failure) - Dormant Projects, H1 2020
  • Chronic Kidney Disease (Chronic Renal Failure) - Dormant Projects, H1 2020 (Contd..1), H1 2020
  • Chronic Kidney Disease (Chronic Renal Failure) - Dormant Projects, H1 2020 (Contd..2), H1 2020
  • Chronic Kidney Disease (Chronic Renal Failure) - Discontinued Products, H1 2020

List of Figures

  • Number of Products under Development for Chronic Kidney Disease (Chronic Renal Failure), H1 2020
  • Number of Products under Development by Companies, H1 2020
  • Number of Products under Development by Universities/Institutes, H1 2020
  • Number of Products by Top 10 Targets, H1 2020
  • Number of Products by Stage and Top 10 Targets, H1 2020
  • Number of Products by Top 10 Mechanism of Actions, H1 2020
  • Number of Products by Stage and Top 10 Mechanism of Actions, H1 2020
  • Number of Products by Routes of Administration, H1 2020
  • Number of Products by Stage and Routes of Administration, H1 2020
  • Number of Products by Top 10 Molecule Types, H1 2020
  • Number of Products by Stage and Top 10 Molecule Types, H1 2020
目次
Product Code: GMDHC12132IDB

Summary:

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Chronic Kidney Disease - Pipeline Review, H1 2020, provides an overview of the Chronic Kidney Disease (Genito Urinary System And Sex Hormones) pipeline landscape.

Chronic kidney disease is the slow loss of kidney function over time. Signs and symptoms of kidney disease include nausea, vomiting, loss of appetite, fatigue and weakness, sleep problems, hiccups and swelling of feet and ankles. The predisposing factors include age, diabetes, high blood pressure, heart disease, smoking, obesity and high cholesterol.

Report Highlights:

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Chronic Kidney Disease - Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Chronic Kidney Disease (Genito Urinary System And Sex Hormones), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Chronic Kidney Disease (Genito Urinary System And Sex Hormones) pipeline guide also reviews of key players involved in therapeutic development for Chronic Kidney Disease (Chronic Renal Failure) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 1, 4, 11, 11, 2, 23, 14 and 2 respectively. Similarly, the Universities portfolio in Phase II and Preclinical stages comprises 1 and 3 molecules, respectively.

Chronic Kidney Disease (Genito Urinary System And Sex Hormones) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Chronic Kidney Disease (Genito Urinary System And Sex Hormones).
  • The pipeline guide reviews pipeline therapeutics for Chronic Kidney Disease (Genito Urinary System And Sex Hormones) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Chronic Kidney Disease (Genito Urinary System And Sex Hormones) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Chronic Kidney Disease (Genito Urinary System And Sex Hormones) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Chronic Kidney Disease (Genito Urinary System And Sex Hormones)

Reasons to Buy:

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Chronic Kidney Disease (Genito Urinary System And Sex Hormones).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Chronic Kidney Disease (Genito Urinary System And Sex Hormones) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Introduction
  • Chronic Kidney Disease (Chronic Renal Failure) - Overview
  • Chronic Kidney Disease (Chronic Renal Failure) - Therapeutics Development
  • Chronic Kidney Disease (Chronic Renal Failure) - Therapeutics Assessment
  • Chronic Kidney Disease (Chronic Renal Failure) - Companies Involved in Therapeutics Development
  • Chronic Kidney Disease (Chronic Renal Failure) - Drug Profiles
  • Chronic Kidney Disease (Chronic Renal Failure) - Dormant Projects
  • Chronic Kidney Disease (Chronic Renal Failure) - Discontinued Products
  • Chronic Kidney Disease (Chronic Renal Failure) - Product Development Milestones
  • Appendix
株式会社グローバルインフォメーション
© Copyright 1996-2020, Global Information, Inc. All rights reserved.